<DOC>
	<DOCNO>NCT02644486</DOCNO>
	<brief_summary>To observe decreased level low-density lipoprotein baseline patient obesity-related glomerulopathy ( ORG ) 12 week Sevelamer Carbonate treatment .</brief_summary>
	<brief_title>A Prospective , Single-center , Randomized , Controlled Study Sevelamer Carbonate Lipid Metabolism Uric Acid Treatment Obesity-Related Glomerulopathy</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Clinical diagnosis obesity diagnose ORG renal biopsy LDL &gt; 3.37mmol/L Proteinuria 0.53.5g/d eGFR ( CKDEPI formula ) &gt; 30ml/min Other concomitant renal disease Endocrine druginduced obesity ; Type 2 diabetes eyes obvious microscopic hematuria ; Swallowing difficulty / severe gastrointestinal dysfunction intestinal obstruction ; severe arrhythmia ; Hypophosphatemia ( &lt; 0.7mmol/L ) ; allergic Sevelamer Carbonate unable well cooperate Females period gestation lactation , refuse use contraception ; participate clinical trial drug within three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>